2. GPCR/G Protein
    Neuronal Signaling
  3. Opioid Receptor
  4. CTOP TFA

CTOP TFA 

Cat. No.: HY-P1329A Purity: 99.93%
COA Handling Instructions

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CTOP TFA Chemical Structure

CTOP TFA Chemical Structure

Size Price Stock Quantity
1 mg USD 250 In-stock
Estimated Time of Arrival: December 31
5 mg USD 750 In-stock
Estimated Time of Arrival: December 31
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of CTOP TFA:

Top Publications Citing Use of Products

1 Publications Citing Use of MCE CTOP TFA

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity[1][2].

IC50 & Target

μ Opioid Receptor/MOR

 

In Vivo

CTOP TFA (0-0.5 nmol, ICV, once) antagonizes the analgesic effect of morphine in a dose-dependent manner[1].
CTOP TFA (0-2 nmol, ICV, once) causes withdrawal hypothermia and a loss of body weight in morphine-dependent animals[1].
CTOP TFA (0-1.5 nmol per side, Intra-VTA injection) enhances extracellular dopamine levels in the nucleus accumbens and dose-dependently enhances locomotor activity[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male CFLP mice (25-30 g)[1]
Dosage: 0, 0.001, 0.05, 0.075, 0.1, and 0.5 nmol (made up in artificial cerebrospinal fluid (CSF) and kept in plastic tubes at -25℃ until use)
Administration: Intracerebroventricular (i.c.v.) administration, once
Result: Antagonized the analgesic effect of morphine in a dose-dependent manner, antagonized the morphine-induced hypermotility in a dose-dependent manner.
Animal Model: Male CFLP mice (25-30 g, Acute dependence to morphine was induced by a single dependence-inducing (100 mg/kg) dose of morphine-HC1)[1]
Dosage: 0, 0.001, 0.05, 0.2, and 2 nmol
Administration: Intracerebroventricular (i.c.v.) administration, once
Result: Decreased the body temperature in a dose-dependent manner, and caused withdrawal hypothermia and a loss of body weight in morphine-dependent animals.
Animal Model: Long-Evans hooded rats (12, male, 350-450 g)[2]
Dosage: 0, 0.015, 0.15, and 1.5 nmol per side
Administration: Intra-VTA (ventral tegmental area) injection
Result: Enhanced extracellular dopamine levels in the nucleus accumbens, dose-dependently increased activity, whereas had no effect on feeding and drinking behavior.
Molecular Weight

1176.28

Appearance

Solid

Formula

C52H68F3N11O13S2
Sequence

Phe-Cys-Tyr-Trp-{Orn}-Thr-{Pen}-Thr-NH2 (Disulfide bridge:Cys2-Pen7)
Sequence Shortening

FCYW{Orn}T{Pen}T-NH2 (Disulfide bridge:Cys2-Pen7)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro: 

H2O : 50 mg/mL (42.51 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.8501 mL 4.2507 mL 8.5014 mL
5 mM 0.1700 mL 0.8501 mL 1.7003 mL
10 mM 0.0850 mL 0.4251 mL 0.8501 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (85.01 mM); Clear solution; Need ultrasonic

*All of the co-solvents are available by MCE.
Purity & Documentation

Purity: 99.93%

COA (247 KB) LCMS (98 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

CTOPOpioid Receptorμ-opioid receptorKORpepideMorphine-induced analgesiaHypermotilityventral tegmental areaOpioidMu-opioid receptorNucleus accumbensLocomotor activityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CTOP TFA
Cat. No.:
HY-P1329A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email address *

Phone number

 

Department *

Organization name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.